History and perspectives of hypocretin/orexin research in sleep medicine

Sleep and Biological Rhythms

Volumn 1, Issue 1, 2003, Pages 43-54

  Nishino, Seiji ^a   Yoshida, Yasushi ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

energy homeostasis; hypocretin orexin; narcolepsy; sleep wake regulation

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; GALANIN; MODAFINIL; OREXIN;

AROUSAL; CATAPLEXY; CHOLINERGIC SYSTEM; DAYTIME SOMNOLENCE; ENERGY METABOLISM; FEEDING; FOOD INTAKE; GENE MUTATION; HUMAN; HYPERSOMNIA; HYPOTHALAMUS; MONOAMINERGIC SYSTEM; NARCOLEPSY; NEUROENDOCRINE SYSTEM; NONHUMAN; PATHOGENESIS; PERIODIC LIMB MOVEMENT DISORDER; PREOPTIC AREA; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SLEEP; SLEEP DISORDERED BREATHING; SLEEP WAKING CYCLE;

EID: 84979901961     PISSN: 14469235     EISSN: 14798425     Source Type: Journal    
DOI: 10.1046/j.1446-9235.2003.00001.x     Document Type: Review

References (92)

1. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol. 1997; 52: 27–78.
2. Nishino S, Okura M, Mignot M. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med. Rev. 2000; 4: 57–99.
3. Beuckmann CT, Willie JT, Hara J, Yamanaka K, Sakurai T, Yanagisawa M. Orexin neuron-ablated mice fail to increase vigilance and locomotor activity in response to fasting. Sleep 2002; 25 (Suppl.): A353–4.
4. Chemelli RM, Willie JT, Sinton CM et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437–51.
5. Hara J, Beuckmann CT, Nambu T et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30: 345–54.
6. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50 (Suppl.): S16–22.
7. Honda Y, Doi Y, Juji T, Satake M. Positive DR2 as a prerequisite for the development of narcolepsy. Folia Psychiatr. Neurol. Jpn. 1984; 38: 360.
8. Matsuki K, Grumet FC, Lin X, Guilleminault C, Dement WC. DQ rather than DR gene marks susceptibility to narcolepsy. Lancet 1992; 339: 626–8.
9. Gélineau JBE. De la narcolepsie. Gazette Des Hôpitaux 1880; 53: 626–8.
10. Lin L, Faraco J, Li R et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365–76.
11. Peyron C, Faraco J, Rogers W et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 2000; 6: 991–7.
12. Nishino S, Ripley B, Overeem S et al. Low CSF hypocre-tin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. 2001; 50: 381–8.
13. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 39–40.
14. Kanbayashi T, Inoue Y, Chiba S et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J. Sleep Res. 2002; 11: 91–3.
15. Mignot E, Lammers GJ, Ripley B et al. The roles of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 2002; 59: 1553–62.
16. Thannickal TC, Moore RY, Nienhuis R et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469–74.
17. Ripley B, Overeem S, Fujiki N et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001; 57: 2253–8.
18. Alaila SL. Life effects of narcolepsy: measures of negative impact, social support and psychological well-being. In: Goswanmi M, Pollak CP, Cohen FL, Thorpy MJ, Kavey NB, eds. Loss, Grief and Care: Psychosocial Aspects of Narcolepsy. New York: Haworth Press, 1992; 1–22.
19. Higuchi S, Usui A, Murasaki M et al. Plasma orexin-A is lower in patients with narcolepsy. Neurosci. Lett. 2002; 318: 61–4.
20. Nishino S, Mignot E. Article reviewed: Plasma orexin-A is lower in patients with narcolepsy. Sleep Res. Med. 2002; 3: 377–8.
21. American Narcolepsy Association. Stimulant medication survey. The Eye Opener 1992; 1: 1–3.
22. De Lecea L, Kilduff TS, Peyron C et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl Acad. Sci. USA 1998; 95: 322–7.
23. Sakurai T, Amemiya A, Ishil M et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573–85.
24. Willie JT, Chemelli RM, Sinton CM, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Ann. Rev. Neurosci. 2001; 24: 429–58.
25. Jones BE. Basic mechanism of sleep-wake states. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. Philadelphia: W.B. Saunders Company, 1994; 145–62.
26. Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997; 276: 1265–8.
27. Hayaishi O. Molecular genetic studies on sleep-wake regulation, with special emphasis on the prostaglandin D (2) system. J. Appl. Physiol. 2002; 92: 863–8.
28. Krueger JM, Obal FJ, Fang J, Kubota T, Taishi P. The role of cytokines in physiological sleep regulation. Ann. N Y Acad. Sci. 2001; 933: 211–21.
29. Sakurai T. Roles of orexins in regulation of feeding and wakefulness. Neuroreport 2002; 13: 987–95.
30. Peyron C, Tighe DK, van den Pol AN et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 1998; 18: 9996–10 015.
31. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res. 1999; 827: 243–60.
32. Bourgin P, Huitron-Resendiz S, Spier AD et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J. Neurosci. 2000; 20: 7760–5.
33. Hagan JJ, Leslie RA, Patel S et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl Acad. Sci. USA 1999; 96: 10 911–16.
34. Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur. J. Neurosci. 2000; 12: 726–30.
35. Ripley B, Fujiki N, Okura M, Mignot E, Nishino S. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol. Dis. 2001; 8: 525–34.
36. Marcus JN, Aschkenasi CJ, Lee CE et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 2001; 435: 6–25.
37. Eriksson KS, Sergeeva O, Brown RE, Haas HL. Orexin/hypocretin excites the histaminergic neurons of the tuber-omammillary nucleus. J. Neurosci. 2001; 21: 9273–9.
38. Yamanaka A, Tsujino N, Funahashi H et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem. Biophys. Res. Comm. 2002; 290: 1237–45.
39. Huang ZL, Qu WM, Li WD et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl Acad. Sci. USA 2001; 98: 9965–70.
40. Nishino S, Fujiki N, Ripley B et al. Decreased brain his-tamine contents in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci. Lett. 2001; 313: 125–8.
41. Eggermann E, Serafin M, Bayer L et al. Orexins/hypocre-tins excite basal forebrain cholinergic neurons. Neuroscience 2001; 108: 177–81.
42. Nakamura T, Uramura K, Nambu T et al. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res. 2000; 873: 181–7.
43. Xi MC, Morales FR, Chase MH. Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res. 2001; 901: 259–64.
44. Beuckmann CT, Yanagisawa M. Orexins: from neu-ropeptides to energy homeostasis and sleep/wake regulation. J. Mol. Med. 2002; 80: 329–42.
45. Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J. Neurosci. 2002; 22: 6742–6.
46. Broughton R, Dunham W, Newman J, Lutley K, Dushesne P, Rivers M. Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched control. Electroencephalogr. Clin. Neurophysiol. 1988; 70: 473–81.
47. Kaitin KI, Kilduff TS, Dement WC. Sleep fragmentation in genetically narcoleptic dogs. Sleep 1986; 9: 116–19.
48. Lucas EA, Foutz AS, Dement WC, Mitler MM. Sleep cycle organization in narcoleptic and normal dogs. Physiol. Behav. 1979; 23: 737–43.
49. Nishino S, Riehl J, Hong J, Kwan M, Reid M, Mignot E. Is narcolepsy REM a sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neurosci. Res. 2000; 38: 437–46.
50. Billiard M. Idiopathic hypersomnia. Neurol. Clin. 1996; 14: 573–82.
51. Yoshida Y, Fujiki N, Nakajima T et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur. J. Neurosci. 2001; 14: 1075–81.
52. Aston-Jones G, Chen S, Zhu Y, Oshinsky ML. A neural circuit for circadian regulation of arousal. Nat. Neurosci. 2001; 4: 732–8.
53. Bishop C, Rosenthal L, Helmus T, Roehrs T, Roth T. The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness. Sleep 1996; 19: 727–30.
54. Fukuda K, Miyasita A, Inugami M, Ishihara K. High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan. Sleep 1987; 10: 279–86.
55. Ohayon MM, Priest RG, Caulet M, Guilleminault C. Hypnagogic and hypnopompic hallucinations: pathological phenomena? Br. J. Psych. 1996; 169: 459–67.
56. Sherin J, Shiromani P, McCarley R, Saper C. Activation of ventrolateral preoptic neurons during sleep. Science 1996; 271: 216–20.
57. Gong H, Szymusiak R, King J, Steininger T, McGinty D. Sleep-related c-Fos protein expression in the preoptic hypothalamus: effects of ambient warming. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000; 279: R2079–88.
58. Economo C. Sleep as a problem of localization. Am. J. Neuropsych. 1930; 71: 249–59.
59. Moruzzi G, Magoun HW. Brain stem reticular formation and activation of the EEG. Electroencephalogr. Clin. Neurophysiol. 1949; 1: 455–73.
60. Aserinsky E, Kleitman N. Regularly occurring periods of eye motility, and concomitant phenomena during sleep. Science 1953; 118: 273–4.
61. McGinty DJ, Sterman MB. Sleep suppression after basal forebrain lesions in the cat. Science 1968; 160: 1253–5.
62. Szymusiak R, McGinty D. Sleep-related neuronal discharge in the basal forebrain of cats. Brain Res. 1986; 370: 82–92.
63. Sherin JE, Elmquist JK, Torrealba F, Saper CB. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J. Neurosci. 1998; 18: 4705–21.
64. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001; 24: 726–31.
65. Deurveilher B, Burns J, Semba K. Indirect projections from the suprachiasmatic nucleus to wake-related neuronal groups in the forebrain and brainstem. Sleep 2001; 24 (Suppl.): A142.
66. Edwards CM, Abusnana S, Sunter D, Murphy KG, Ghatei MA, Bloom SR. The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. J. Endocrinol. 1999; 160: R7–12.
67. Honda Y, Doi Y, Ninomiya R, Ninomiya C. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 1986; 9: 254–9.
68. Lammers GJ, Pijl H, Iestra J, Langius JAE, Buunk G, Meinders AE. Spontaneous food choice in narcolepsy. Sleep 1996; 19: 75–6.
69. Mayer G, Hellman F, Leonhardt E, Sommenschein W, Meir-Ewert K. Circadian temperature- and activity rhythms in unmedicated narcolepsy patients. J. Sleep Res. 1994; 3: 161.
70. Sachs C, Kaisjer L. Autonomic control of cardiovascular reflexes in Narcolepsy. J. Neurol. Neurosurg. Psychiatry 1980; 43: 535–9.
71. Overeem S, Koh SW, Pijl H, Lammers GJ, Meinders AE. Body weight and composition in patients with narcolepsy versus idiopathic hypersomnia. Sleep 2002; 25 (Suppl.): A79.
72. Dewasmes G, Duchamp C, Minaire Y. Sleep changes in fasting rats. Physiol. Behav. 1989; 46: 179–84.
73. Yamanaka K, Hara J, Tsujino N, Beuckmann C, Yanagisawa M, Sakurai T. Regulation of orexin neurons by periferal nutritional signals: roles of leptin, ghrelin and glucose. Sleep 2002; 25 (Suppl.): A356–7.
74. Allen RP, Mignot E, Ripley B, Nishino S, Earley CJ. Increased CSF hypocretin-1 (orexin A) in restless legs syndrome. Neurology 2002; 59: 639–41.
75. Wittig R, Zorick F, Piccione P, Sicklesteel J, Roth T. Narcolepsy and disturbed nocturnal sleep. Clin. Electroencephalogr. 1983; 14: 130–4.
76. Boivin DB, Montplaisir J, Poirier G. The effects of L-DOPA on periodic leg movements and sleep organization in narcolepsy. Clin. Neuropharmacol. 1989; 12: 339–45.
77. Okura M, Fujiki N, Ripley B et al. Narcoleptic canines display periodic leg movements during sleep. Psychiatry Clin. Neurosci. 2001; 55: 243–4.
78. Amitai N, Okura M, Fujiki N et al. The dopaminergic system and sleep, and sleep-related involuntary movements. Sleep 2001; 24 (Suppl.): A99.
79. Date Y, Ueta Y, Yamashita H et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc. Natl Acad. Sci. USA 1999; 96: 748–53.
80. Jaszberenyi M, Bujdoso E, Pataki I, Telegdy G. Effects of orexins on the hypothalamic-pituitary-adrenal system. J. Neuroendocrinol. 2000; 12: 1174–8.
81. Kuru M, Ueta Y, Serino R et al. Centrally administered orexin/hypocretin activates HPA axis in rats. Neuroreport 2000; 11: 1977–80.
82. Bingham S, Davey PT, Babbs AJ et al. Orexin-A, an hypothalamic peptide with analgesic properties. Pain 2001; 92: 81–90.
83. Irving EA, Harrison DC, Babbs AJ et al. Increased cortical expression of the orexin-1 receptor following permanent middle cerebral artery occlusion in the rat. Neurosci. Lett. 2002; 324: 53–6.
84. Overeem S, Dalmau J, Bataller L et al. Secondary narcolepsy in patients with paraneoplastic anti-Ma2 antibodies is associated with hypocretin deficiency. J. Sleep Res. 2001; 11: 166–7.
85. Vankova J, Nevsimalova S, Elleder M, Mignot E, Nishino S. Hypocretin system dysfunction in Niemann-pick disease (type C). J. Sleep Res. 2002; 11 (Suppl. 1): 234–5.
86. Laberge L, Begin P, Leblond A, Montplaisir J, Mathieu J. Excessive daytime sleepiness in myotonic dystrophy. Sleep 2002; 25 (Suppl.): A265.
87. Nishino S, Ripley B, Mignot E, Benson KL, Zarcone VP. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 2002; 110: 1–7.
88. Salomon RM, Ripley B, Kennedy J et al. Diurnal Variation of CSF hypocretin-1 (Orexin A) levels in control and depressed subjects. Sleep 2002; 25 (Suppl.): A12.
89. Franken P, Tobler I, Borbely AA. Sleep homeostasis in the rat: simulation of the time course of EEG slow-wave activity. Neurosci. Lett. 1991; 130: 141–4.
90. Honda K, Riehl J, Mignot E, Nishino S. Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep. Neuroreport 1999; 10: 3717–24.
91. Okura M, Honda K, Riehl J, Mignot E, Nishino S. Roles of diencephalic dopaminergic cell groups in regulation of cataplexy in canine narcolepsy. Sleep 1999; 22 (Suppl.): S1.
92. Mignot E, Taheri S, Nishino S. Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorder. Nat. Neurosci. 2002; 5 (Suppl.): 1071–5.